Our study confirms the class effect of PPARγ agonists and MEK inhibitors in promoting adipogenesis in breast cancer cells, highlighting their potential interchangeability in clinical applications and offering a promising option for patients with treatment-resistant TNBC. This evidence concerns the gene MAP2K7 and breast carcinoma.